CClinicalTrials.gg
Status unknownNCT03803449Updated Jan 14, 2019

Patient Satisfaction and Safety With Propofol Based Sedation With or Without Fentanyl for Gastrointestinal Endoscopy

A Phase 4 interventional study of 50-200mg propofol and 50ug fentanyl in Patient Satisfaction, sponsored by Shandong University. Status unknown. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-14.

Sponsored by Shandong University · Phase 4, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Patient satisfaction and safety with propofol based sedation with or without fentanyl for gastrointestinal endoscopy

Read the detailed description

This study divide patients into two groups, one will be given propofol midazolam and fentanyl; another group was given propofol with midazolam without fentanyl; to observe two groups of patients blood pressure, body movement, and propofol dosage , and the difference in operator satisfaction, and how many people need to give fentanyl again; and two groups of patients after the operation of the reaction, if there are dizziness, nausea, and other adverse reactions; finally, the differences of these two schemes in different populations were analyzed, and the rationalization and individualized medication will be put forward.

02

Conditions studied

  • Patient Satisfaction

Keywords

  • propofol
  • fentanyl
  • gastrointestinal endoscopy
03

In context

Lead sponsor

Shandong University is the lead sponsor of 284 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients aged 18 or older
  • Patients scheduled for an outpatient gastrointestinal endoscopy by the principal investigator.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of colorectal surgery
  • Patients with ASA class 4 or 5,
  • Patients with pre-existing hypoxaemia (SpO2\<90%),
  • Patients with hypotension (SBP\<90mmHg)
  • Patients with bradycardia (HR\<50 bpm)
  • patients with severe chronic renal failure (creatinine clearance\<30 ml/min)
  • patients with uncontrolled hypertension (systolic blood pressure>170 mm Hg, diastolic blood pressure>100 mm Hg)
  • patients with pregnancy or lactation
  • Patients hemodynamically unstable
  • Patients unable to give informed consent
  • Patients with a history of drug allergies;
05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Active comparator
    Control group

    Participants are given standard regimen: 50-200mg propofol and 1 mg midazolam

    Drug: 50-200mg propofol · Drug: 1 mg midazolam

  • Experimental
    Fentanyl group

    Participants are given intervention regimen: 50ug fentanyl, plus 50-200mg propofol and 1 mg midazolam.

    Drug: 50-200mg propofol · Drug: 50ug fentanyl · Drug: 1 mg midazolam

Interventions

  • Drug50-200mg propofol

    participants in both groups are given standard regimen including 50-200mg propofol.

    Also known as: Jingan, J20110055

  • Drug50ug fentanyl

    participants in fentanyl group are given intervention regimen: 50ug fentanyl.

    Also known as: Yichang, H42022076

  • Drug1 mg midazolam

    participants in both groups are given standard regimen including 1 mg midazolam.

    Also known as: Liyuexi, H10980025

06

What researchers measure

Primary outcomes

  1. Satisfaction assessed by the rate of vomit and diazzy after the procedure

    Rates of vomit and diazzy of patients after the procedure between the two groups

    Time frame: half a year

Secondary outcomes

  1. Safety assessed by the rate of hypoxia during the procedure

    Hypoxia, defined as peripheral oxygen saturation \<90% for \>30 seconds

    Time frame: half a year

  2. Safety assessed by the rate of hypotention during the procedure

    Hypotension, defined as systolic blood pressure \<90 mmHg

    Time frame: half a year

  3. Safety assessed by the rate of hyoxemia during the procedure

    Hypoxia, defined as peripheral oxygen saturation \<90% for \>30 seconds

    Time frame: half a year

  4. Safety assessed by the rate of breadycardia during the procedure

    Bradycardia, defined as heart rate \<50 beats/min

    Time frame: half a year

  5. Safety assessed by the rate of required airway management during the procedure

    Required airway management such as jaw lifting, mask ventilation, or tracheal intubation in severe hypoxia

    Time frame: half a year

  6. Safety assessed by the rate of involuntary movement during the procedure

    Involuntary movements, defined as unconscious movements requiring restraint or severe limb movement interrupting the endoscopy procedure

    Time frame: half a year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03803449
Lead sponsor
Shandong University
Responsible party
Yanqing Li (Principal Investigator, Shandong University) — Principal investigator
First posted
Jan 14, 2019
Start date
Jan 1, 2019 (estimated)
Primary completion
Jul 30, 2019 (estimated)
Completion
Oct 30, 2019 (estimated)
Last update
Jan 14, 2019

Study contacts

jing liu
Contact
1057986797@qq.com
+86-18560083755
yanqing li, Dr.
study chair · Qilu Hospital of Shandong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion